Hot Flashes and Neurovascular Function in Women
NCT05193968 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2025-06-03
Summary
Women who experience hot flashes are at greater risk for hypertension and other cardiovascular disease. Neurovascular control mechanisms are likely to play an important role in this relationship. As such, these studies are designed to provide a major step forward in understanding the link between hot flashes and neurovascular dysfunction and, by extension, cardiovascular disease in women.
Conditions
- Hot Flashes
- Menopause
- Vasomotor System; Labile
Interventions
- OTHER
-
Sympathoexcitatory stressors
Muscle sympathetic nerve activity will be measured continuously at baseline and in response to sympathoexcitatory stressors, including a Valsalva maneuver, isometric handgrip exercise, a cold pressor test, and stepped hypercapnia.
- DRUG
-
Sodium Nitroprusside
Sodium nitroprusside, used to test endothelium-independent vasodilation, will be infused through a brachial artery catheter at 0.25, 0.5, 1.0 and 2.0 ug/100ml tissue/min.
- DRUG
-
Acetylcholine
Acetylcholine, used to test endothelium-dependent vasodilation, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 μg/100ml tissue/min
- DRUG
-
Terbutaline
Terbutaline, a β2-Adrenergic selective agonist, will be infused through a brachial artery catheter at 0.1, 0.5, 1.0, and 2.0 μg/100ml tissue/min.
- DRUG
-
Norepinephrine
Norepinephrine, an α-adrenergic vasoconstricting agent, will be infused through a brachial artery catheter at 1.0, 2.0, 4.0, and 8.0 ng/100ml tissue/min
Sponsors & Collaborators
-
National Institutes of Health (NIH)
collaborator NIH -
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH - lead OTHER
Principal Investigators
-
Sarah Baker, PhD · Mayo Clinic
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 40 Years
- Max Age
- 60 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-02-24
- Primary Completion
- 2026-12-31
- Completion
- 2026-12-31
Countries
- United States
Study Locations
More Related Trials
-
Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
NCT00995072 ·Status: COMPLETED ·Phase: NA
-
Effect of BMS-914392 on Pharmacokinetics of Metoprolol
NCT01211821 ·Status: COMPLETED ·Phase: PHASE1
-
Nebivolol Versus Metoprolol: Sodium Sensitivity
NCT00992056 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients
NCT01502787 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques
NCT01230892 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Norepinephrine Levels and Sympathetic Nervous System Activity
NCT00001329 ·Status: COMPLETED
-
Effect of Nebivolol on Oxidative Stress and Endothelial Progenitor Cells
NCT01041287 ·Status: COMPLETED ·Phase: PHASE4
-
Cognitive/Cerebrovascular Consequences of HTN Treatment
NCT00151138 ·Status: COMPLETED ·Phase: NA
-
Sympathetic and Vascular Function in Takotsubo Syndrome
NCT05768542 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
NCT05219799 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart
NCT01961323 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers
NCT02264002 ·Status: COMPLETED ·Phase: PHASE1
-
Nebivolol and Endothelial Regulation of Fibrinolysis (NERF)
NCT01595516 ·Status: COMPLETED ·Phase: PHASE4
-
Cardiovascular Medication Use Before First Myocardial Infarction
NCT01692795 ·Status: COMPLETED
-
Phenylephrine Versus Norepinephrine in Ophthalmic Surgery
NCT01609491 ·Status: COMPLETED ·Phase: NA
-
Tilt-Table Study of the Clinical Efficacy of Midodrine in Symptomatic Orthostatic Hypotension
NCT01518946 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Study of Pyridostigmine in Heart Failure
NCT01415921 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
NCT00829296 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Intravenous Norepinephrine for Orthostatic Hypotension
NCT01285908 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pathophysiology of Cardiometabolic Risk Factors in African Americans
NCT01122407 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety Evaluation of ECG Intervals and Blood Pressure in Normal Healthy Volunteers After Use of Nebivolol, Atenolol, Moxifloxacin, or Placebo
NCT00158093 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
NCT00648895 ·Status: COMPLETED ·Phase: PHASE3
-
Non-Pharmacologic Therapy for Neurocardiogenic Syncope
NCT00096902 ·Status: COMPLETED ·Phase: PHASE2
-
Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?
NCT01605370 ·Status: TERMINATED ·Phase: PHASE4
-
Systolic Hypertension in the Elderly Program (SHEP)
NCT00000514 ·Status: COMPLETED ·Phase: PHASE3